EMR
Emerson Electric Co.
EMR has a slight edge over RKLB overall, supported by lower modeled downside and stronger fundamentals.
RKLB
Rocket Lab USA, Inc.
RKLB offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
EMR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
EMR's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
RKLB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
RKLB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
EMR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 10x | $49.84 | -70% |
| Fair | 22x | $107 | -36% |
| Forward | 23x | $167 | — |
| Expensive | 33x | $160 | -4.2% |
| Current | 35x | $167 | — |
Historical ranges are pointers, not guarantees.
EMR's PE is in its expensive range at 35x. If earnings grow as analysts expect, today's price would be 23x next year's earnings, in its fair range.
RKLB PE Valuation
RKLB has no meaningful PE right now: it lost money over the past year.
EMR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for EMR, with profitability improving.
RKLB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RKLB's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
EMR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.30 | +53% |
| Q3 2026 | $4.78 | +18% |
| Q2 2026 | $4.57 | -1.7% |
| Q1 2026 | $4.33 | +3.6% |
| Q4 2025 | $4.09 | -2.4% |
| Q3 2025 | $4.04 | +18% |
| Q2 2025 | $4.65 | +56% |
| Q1 2025 | $4.18 | -78% |
| Q4 2024 | $4.19 | -78% |
EMR has the edge over RKLB on earnings quality, reporting a profit while its opponent remains loss making.
RKLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.36 | +$0.03 |
| Q2 2026 | -$0.27 | +$0.19 |
| Q1 2026 | -$0.32 | +$0.09 |
| Q4 2025 | -$0.37 | +$0.01 |
| Q3 2025 | -$0.39 | -$0.02 |
| Q2 2025 | -$0.46 | -$0.11 |
| Q1 2025 | -$0.41 | -$0.04 |
| Q4 2024 | -$0.38 | $0.00 |
RKLB is still losing money, but less than at its worst: $0.36 per share over the past year, against $0.46 at its worst in mid-2025.
EMR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.2B | +7.1% |
| Q2 2026 | $4.9B | +7% |
| Q1 2026 | $4.6B | +2.9% |
| Q4 2025 | $4.3B | +4.1% |
| Q3 2025 | $4.9B | +5.1% |
| Q2 2025 | $4.6B | +3.9% |
| Q1 2025 | $4.4B | +1.3% |
| Q4 2024 | $4.2B | +1.4% |
EMR's revenue has grown year over year for 12 quarters in a row: $5.2B last quarter, up 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +2.9 points |
| Q2 2026 | 19% | +2.7 points |
| Q1 2026 | 17% | +3.2 points |
| Q4 2025 | 18% | -0.7 points |
| Q3 2025 | 16% | +1.7 points |
| Q2 2025 | 16% | +5.7 points |
| Q1 2025 | 14% | -0.7 points |
| Q4 2024 | 19% | +15 points |
EMR has the edge over RKLB on profitability, with a higher operating margin.
RKLB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $267.8M | +73% |
| Q2 2026 | $234.1M | +62% |
| Q1 2026 | $200.3M | +63% |
| Q4 2025 | $179.7M | +36% |
| Q3 2025 | $155.1M | +48% |
| Q2 2025 | $144.5M | +36% |
| Q1 2025 | $122.6M | +32% |
| Q4 2024 | $132.4M | +121% |
RKLB has the edge over EMR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | +8.5 points |
| Q2 2026 | -25% | +17 points |
| Q1 2026 | -28% | +20 points |
| Q4 2025 | -28% | +11 points |
| Q3 2025 | -38% | +12 points |
| Q2 2025 | -41% | -0.5 points |
| Q1 2025 | -48% | -1.9 points |
| Q4 2024 | -39% | +41 points |
RKLB's operating margin was −30% last quarter, up 8.5 points from the same quarter a year ago.
EMR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $917M | +8.9% |
| Q2 2026 | $1.3B | +35% |
| Q1 2026 | $694M | +351% |
| Q4 2025 | $602M | -13% |
| Q3 2025 | $842M | -8.1% |
| Q2 2025 | $977M | -2.1% |
| Q1 2025 | $154M | -77% |
| Q4 2024 | $694M | +105% |
EMR has the edge over RKLB on cash generation, producing positive trailing cash flow while its opponent burns cash.
RKLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.9M | +$45.5M |
| Q2 2026 | -$110.1M | -$54.8M |
| Q1 2026 | -$77.4M | +$5.5M |
| Q4 2025 | -$114.2M | -$90.2M |
| Q3 2025 | -$69.4M | -$27.5M |
| Q2 2025 | -$55.3M | -$26.9M |
| Q1 2025 | -$82.9M | -$61.1M |
| Q4 2024 | -$23.9M | +$28.7M |
RKLB has burned cash in almost every quarter: −$326M over the past year, against −$232M the year before.
EMR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +900K shares |
| 1 year | -0.8% | -4.7M shares |
| 3 years | -2.7% | -15.3M shares |
| 5 years | -6.6% | -39.8M shares |
| Available history | -8.5% | -52.1M shares |
EMR has the edge over RKLB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $102M |
| Q2 2026 | $356M |
| Q1 2026 | $292M |
| Q4 2025 | $250M |
| Q3 2025 | $20M |
| Q2 2025 | $25M |
| Q1 2025 | $223M |
| Q4 2024 | $899M |
EMR spent $1B buying back its own shares over the past year, down 14% from the year before.
RKLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +22.6M shares |
| 1 year | +23% | +124M shares |
| 3 years | +35% | +168M shares |
| 5 years | +46% | +204M shares |
RKLB has 652M diluted shares, up 23% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
EMR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.3x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 3.0x | Elevated |
| Q4 2024 | 1.1x | Healthy |
EMR's net debt is about 2.1 years of its operating earnings (EBITDA), down from 2.6 years a year ago.
RKLB Net Leverage
RKLB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EMR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.0 | Neutral |
| Stochastic | 74.4 | Neutral |
EMR's weekly RSI is 64 (neutral) and its Stochastic is 74 (neutral).
RKLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 27.6 | Neutral |
RKLB's weekly RSI is 47 (neutral) and its Stochastic is 28 (neutral).
EMR PE vs Industrials Sector
| Metric | EMR | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 24x | 45% above |
| PE % | 89 | 58 | 31 pts above |
EMR is trading at 35x earnings, a 45% premium to the Industrials sector's median of 24x.
RKLB PE vs Industrials Sector
RKLB has no meaningful PE right now: it lost money over the past year.
EMR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $162.4 | 2.8% above |
| 20 week MA | $155.2 | 7.6% above |
| 50 week MA | $146.6 | 14% above |
| 100 week MA | $135.9 | 23% above |
| 200 week MA | $117.9 | 42% above |
EMR has the edge over RKLB on trend strength, trading above more of its moving averages.
RKLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.4 | 4.3% above |
| 20 week MA | $68.1 | 5.9% below |
| 50 week MA | $77.6 | 17% below |
| 100 week MA | $56.5 | 13% above |
| 200 week MA | $31.4 | 104% above |
RKLB's trend is mixed: it's above three of its five weekly moving averages, and 104% above its 200-week average.
EMR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $76.5 | $80.0 | +4.5% |
| 2021 | $80.0 | $91.3 | +14% |
| 2022 | $91.3 | $95.5 | +4.7% |
| 2023 | $95.5 | $97.3 | +1.9% |
| 2024 | $97.3 | $125.7 | +29% |
| 2025 | $125.7 | $135.7 | +8% |
| 2026 YTD | $135.7 | $166.9 | +23% |
EMR has the edge over RKLB on returns for 2026, with the stronger performance.
RKLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.82 | $10.3 | +4.9% |
| 2021 | $10.3 | $12.0 | +17% |
| 2022 | $12.0 | $3.77 | -69% |
| 2023 | $3.77 | $5.53 | +47% |
| 2024 | $5.53 | $27.2 | +392% |
| 2025 | $27.2 | $70.7 | +160% |
| 2026 YTD | $70.7 | $64.1 | -9.3% |
RKLB's yearly returns have swung widely, from +392% in 2024 to −69% in 2022. It's down 9.3% so far in 2026.